Xolair improves patients' asthma-related quality of life

Results of a clinical study presented at a local congress of the Korean Academy of Asthma, Allergy and Clinical Immunology show that Xolair (omalizumab) reduced the rate of severe asthma exacerbations in patients with inadequately controlled severe persistent asthma, who are at high risk of life-threatening attacks.

Xolair also significantly improved patients' asthma-related quality of life....